196 related articles for article (PubMed ID: 36581998)
41. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
42. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
[TBL] [Abstract][Full Text] [Related]
43. The atypical ubiquitin ligase RNF31 stabilizes c-Myc via epigenetic inactivation of FBXO32 and promotes cancer development.
Chen Z; Ren D; Lv J; Xu Y; Xie M; He X; Shi W; Qian Q; Jing A; Ma X; Qin J; Ding Y; Geng T; Ma J; Liu W; Liu S; Ji J
Cell Signal; 2023 Jul; 107():110677. PubMed ID: 37028779
[TBL] [Abstract][Full Text] [Related]
44. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
45. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
46. Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
Wang Z; Wang F; Ding XY; Li TE; Wang HY; Gao YH; Wang WJ; Liu YF; Chen XS; Shen KW
Cancer Lett; 2022 Feb; 527():174-190. PubMed ID: 34929335
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
An P; Li J; Lu L; Wu Y; Ling Y; Du J; Chen Z; Wang H
Eur J Pharmacol; 2019 Feb; 845():16-23. PubMed ID: 30582912
[TBL] [Abstract][Full Text] [Related]
48. DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
Liu J; Li H; Mao A; Lu J; Liu W; Qie J; Pan G
Cell Cycle; 2020 Dec; 19(24):3622-3631. PubMed ID: 33300431
[TBL] [Abstract][Full Text] [Related]
49. RNF31 promotes proliferation and invasion of hepatocellular carcinoma via nuclear factor kappaB activation.
Hoshino K; Nakazawa S; Yokobori T; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Araki K; Harimoto N; Tokunaga F; Shirabe K
Sci Rep; 2024 Jan; 14(1):346. PubMed ID: 38172174
[TBL] [Abstract][Full Text] [Related]
50. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
51. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
52. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
[TBL] [Abstract][Full Text] [Related]
53. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
54. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Tang J; Tian Z; Liao X; Wu G
Int J Biol Sci; 2021; 17(2):417-429. PubMed ID: 33613102
[TBL] [Abstract][Full Text] [Related]
55. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer.
Zhang J; Zhang G; Zhang W; Bai L; Wang L; Li T; Yan L; Xu Y; Chen D; Gao W; Gao C; Chen C; Ren M; Jiao Y; Qin H; Sun Y; Zhi L; Qi Y; Zhao J; Liu Q; Liu H; Wang Y
Cell Death Differ; 2022 Nov; 29(11):2247-2261. PubMed ID: 35538152
[TBL] [Abstract][Full Text] [Related]
56. LncRNA GHET1 Promotes Hypoxia-Induced Glycolysis, Proliferation, and Invasion in Triple-Negative Breast Cancer Through the Hippo/YAP Signaling Pathway.
Wang Y; Liu S
Front Cell Dev Biol; 2021; 9():643515. PubMed ID: 33869194
[TBL] [Abstract][Full Text] [Related]
57. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
[TBL] [Abstract][Full Text] [Related]
58. YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1/PD-L1 pathway in breast cancer.
Wu Q; Xu Y; Li X; Liu H; You T; Cai T; Yang F
Int J Biochem Cell Biol; 2022 Dec; 153():106314. PubMed ID: 36265523
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia-induced YAP activation and focal adhesion turnover to promote cell migration in mesenchymal TNBC cells.
Nguyen TMH; Lai YS; Chen YC; Lin TC; Nguyen NT; Chiu WT
Cancer Med; 2023 Apr; 12(8):9723-9737. PubMed ID: 36757143
[TBL] [Abstract][Full Text] [Related]
60. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]